The study is an observational multicenter evaluation of participants with colorectal cancer (CRC) who will receive longitudinal plasma ctDNA biomarker profiling in addition to their standard-of-care therapy and disease surveillance.
Study Type
OBSERVATIONAL
Enrollment
300
No intervention
Mercy Clinic Oncology - Fort Smith
Fort Smith, Arkansas, United States
Recurrence-Free Survival
Recurrence-Free Survival as assessed by standard radiographic imaging, measured from the day of completion of definitive treatment to first radiographic recurrence or death
Time frame: 2 years
Sensitivity
Sensitivity defined as the proportion of participants who develop recurrence who have ctDNA detected.
Time frame: 2 years
Specificity
Specificity defined as the proportion of participants who do not develop recurrence who do not have ctDNA detected.
Time frame: 2 years
Positive Predictive Value
Positive predictive value (PPV) defined as the proportion of participants who have ctDNA detected who recur.
Time frame: 2 years
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
MemorialCare
Fountain Valley, California, United States
RECRUITINGThe Center for Cancer and Blood Disorders
Bethesda, Maryland, United States
RECRUITINGMercy Clinic Oncology and Hematology - Joplin
Joplin, Missouri, United States
RECRUITINGMercy Clinic Cancer and Hematology - Chub O'Reilly Cancer Center
Springfield, Missouri, United States
RECRUITINGWashington University School of Medicine
St Louis, Missouri, United States
RECRUITINGMercy Clinic Oncology and Hematology - Sindelar Cancer Center
St Louis, Missouri, United States
RECRUITINGMercy Clinic Oncology and Hematology - David C. Pratt Cancer Center
St Louis, Missouri, United States
RECRUITINGNebraska Cancer Specialists
Omaha, Nebraska, United States
RECRUITINGSoutheastern Medical Oncology Center
Goldsboro, North Carolina, United States
RECRUITING...and 10 more locations